Operating under our Biopharm Division and Neuromodulation Division, Vivani develops, manufactures, and markets therapies that target chronic conditions with high unmet medical needs.
Our Biopharm Division develops novel, miniature drug implants by leveraging our proprietary NanoPortal™ implant technology for delivering medication steadily over extended periods of time. Our differentiated, drug implant candidates have the potential to ensure patients consistently receive the right dose while potentially avoiding safety concerns that may be associated with fluctuating delivery.
Our Neuromodulation Division, recently organized as Cortigent, Inc., seeks to identify and assess strategic options for advancing visual prosthesis candidates. Our primary focus is developing Orion II – a Visual Cortical Prosthesis System created to bring artificial vision to individuals who are blind due to a wide range of causes.